Blueprint Medicines Corp Corporate Call to Discuss the FDA Approval of AYVAKIT in Advanced SM Transcript
Good afternoon. My name is Erica, and I will be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines Conference Call. (Operator Instructions)
Thank you. Kristin Hodous with Blueprint Medicines, you may begin your conference.
Thank you, operator. Good morning, everyone, and welcome to Blueprint Medicines conference call to discuss the FDA approval of AYVAKIT in advanced SM. You can access the press release announcing the approval as well as the slides that we'll be reviewing today by going to the Investors & Media section of our website at www.blueprintmedicines.com.
With me on the call today are Jeff Albers, our Chief Executive Officer; Becker Hewes, our Chief Medical Officer; and Christy Rossi, our Chief Commercial Officer.
Before we get started, I would like to remind everyone that statements we make on this conference call will
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |